Sutureless Biological Aortic Valve Replacement (Su-AVR) in Redo operations: a retrospective real-world experience report of clinical and echocardiographic outcomes.
Ian CummingsM Yousuf SalmasiHalil Ibrahim BulutAlicja ZientaraMahmoud AlShiekhGeorge AsimakopoulosPublished in: BMC cardiovascular disorders (2024)
The study suggests that su-AVR is a feasible and safe alternative to cAVR in high-risk patients undergoing redo surgery. The use of su-AVR offers comparable outcomes to cAVR, with reduced cross clamp times and a lower incidence of postoperative pacemaker requirement in isolated AVR cases. The results of this study contribute to the growing body of evidence supporting the use of su-AVR in high-risk patients, highlighting its feasibility and safety in redo surgeries.
Keyphrases
- aortic valve replacement
- patients undergoing
- aortic valve
- transcatheter aortic valve implantation
- end stage renal disease
- ejection fraction
- minimally invasive
- chronic kidney disease
- newly diagnosed
- risk factors
- adipose tissue
- left ventricular
- peritoneal dialysis
- type diabetes
- coronary artery disease
- patient reported outcomes
- insulin resistance
- atrial fibrillation
- inferior vena cava
- surgical site infection